CTRI/2013/12/004230尚未招募未知
A MULTICENTRIC, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, 3 ARM, BIOEQUIVALENCE STUDY COMPARING PENTOSAN POLYSULFATE SODIUM, ORAL CAPSULE 100 mg (WATSON PHARMA PVT. LTD.), TO ELMIRON ORAL CAPSULE 100 mg (ORTHOâ??MCNEILâ??JANSSEN PHARMACEUTICALS, INC) AND BOTH ACTIVE TREATMENTS TO PLACEBO (WATSON PHARMA PVT. LTD.) IN THE TREATMENT OF INTERSTITIAL CYSTITIS / BLADDER PAIN SYNDROME
Watson Pharma Pvt Ltd India0 个研究点目标入组 528 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
- 入组人数
- 528
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Ba/be
入排标准
入选标准
- •1. Males and females aged more than 18 years with moderate to severe interstitial cystitis
- •2. Patient has experienced bladder pain, urinary urgency and urinary frequency, each not related to a urinary tract infection, for at least the previous 6 months prior to entry into the study.
- •3. An average voided bladder volume of 50 to 200 mL (as determined over 3 consecutive days documented in the urinary frequency diary).
- •4. Urine culture negative for clinically significant urinary tract infection (at baseline or within 2 weeks prior to baseline visit).
- •5. Urine cytology negative for neoplastic cells (at baseline or within 2 months prior to baseline visit).
- •6. Cystoscopic examination under anesthesia by the investigator showing petechial hemorrhages or ulcers following one or two distentions of the bladder at 80 cm of water pressure for one minute performed within 6 months prior to baseline visit and at least 6 weeks prior to baseline visit. Patients that enter remission after their cystoscopic examination should not be scheduled for their baseline visit until the symptoms reappear.
- •7. Patients currently being treated with Pentosan Polysulfate Sodium may be enrolled in the study if Pentosan Polysulfate Sodium treatment is stopped at least for 4 weeks (wash-out period) prior to baseline visit.
排除标准
- •1. More than 25 voids per day
- •2. Bladder capacity of more than 350 mL during awake exam
- •3. Patient is planning to use intravesical therapy for interstitial cystitis within one month prior to baseline visit.
- •4. Patient planning to use medical treatment for interstitial cystitis within one month prior to baseline visit.
- •5. Patient taking any anticoagulants
- •6. Patient with known aneurysm, thrombocytopenia, hemorrhagic disease, hemophilia, or gastrointestinal ulceration (e.g., active bleeding peptic ulcer disease), polyps, or diverticula.
- •7. Patient with known hypersensitivity to Pentosan Polysulfate Sodium, including excipients (microcrystalline cellulose and magnesium stearate), or heparin.
- •8. Patient who has a history of, or currently has, any of these: Neurogenic bladder or diabetic cystopathy, Pelvic irradiation or chemical cystitis, including that due to cyclophosphamide, Presence of urethral, pelvic, or rectal carcinoma, Benign or malignant bladder tumors, Tuberculous cystitis, Urinary schistosomiasis, Bladder or ureteral calculi, Active genital herpes within 3 months prior to study entry, Urethral and/or bladder obstruction, Augmentation cystoplasty, cystectomy, cystolysis, neurectomy or implanted peripheral nerve stimulator that has affected bladder function.
- •9. Patient has microscopic hematuria as defined as 5 RBC/high power field at baseline visit without a negative workup within the last year.
- •10. Patient has current chronic pain condition
- •11. Patient has clinically significant hepatic disease or clinically significant abnormal liver function tests.
- •Gender specific exclusion criteria:
- •Male: 1) Patient has a post-void residual volume of 150 cc by ultrasound. 2) Patient had a Trans Urethral Resection of Prostate (TURP), Trans Urethral Incision of Prostate (TUIP), Trans Urethral Incision of Bladder Neck (TUIBN), Trans Urethral Microwave Thermotherapy (TUMT), Trans Urethral Needle Ablation (TUNA), balloon dilation of the prostate, open prostatectomy or any other prostate surgery or treatment such as cryotherapy or thermal therapy. 3) Patient has a history of prostate cancer. 4) Patient is currently being treated for chronic bacterial prostatitis.
- •Female: 1) Patient has a positive pregnancy test at the baseline visit, is pregnant or lactating, or is planning to become pregnant during the study period. 2) Patient has a history of uterine, cervical or vaginal cancer during the past 3 years. 3) Patient has clinically significant vaginitis at baseline visit.
研究者
相似试验
已完成
3 期
A CLINICAL STUDY TO FIND OUT THE EFFECTIVENESS AND SAFETY OF BOVINE BONE COLLAGEN PEPTIDE AS A NUTRITIONAL THERAPY IN PATIENTS WITH STAGE II AND STAGE III PRESSURE ULCERCTRI/2009/091/001098itta Gelatin India Limited CochinIndia40
已完成
3 期
A CLINICAL TRIAL TO FIND THE EFFECTIVESS AND SAFETY OF PORK SKIN COLLAGEN PEPTIDE POWDER IN PATIENTS WITH STAGE II AND STAGE III PRESSURE ULCERCTRI/2009/091/001097itta Gelatin India ltd CochinIndia120
进行中（未招募）
1 期
A MULTICENTRE, DOUBLE-BLIND, PLACEBO-CONTROLLED, ASCENDING DOSE, CLINICAL TRIAL OF INTRA-VENOUS MICROPLASMIN ADMINISTRATION IN PATIENTS WITH ACUTE ISCHEMIC STROKE - MITI-IVEUCTR2005-001074-27-GBThromboGenics Ltd.40
已完成
不适用
A MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMISED,PARALLEL-GROUP PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OFMASITINIB IN PATIENTS WITH MILD TO MODERATE ALZHEIMER’S DISEASE-G30G30PER-037-16AB Science,1
进行中（未招募）
1 期
Placebo-controlled study in patients with Parkinson's disease to evaluate the effect of rotigotine on nonmotor symptomsParkinson's diseaseMedDRA version: 14.1Level: PTClassification code 10061536Term: Parkinson's diseaseSystem Organ Class: 10029205 - Nervous system disordersEUCTR2010-021394-37-BECB Pharma SA345